Drugs / girentuximab
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04897763 | Dec 2021 → Aug 2022 | urinary bladder cancer | Institut Cancerologie de l'Ouest | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT00520533 | Feb 2008 → Jul 2011 | renal cell carcinoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT00199888 | Jun 2005 → Mar 2006 | clear cell renal carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00142415 | Feb 2005 → Jan 2011 | renal cell carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT00003102 | Nov 1998 → Apr 2000 | kidney cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06447103 | Aug 2024 → Dec 2029 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02883153 | Dec 2015 → Jun 2017 | renal cell carcinoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01762592 | Dec 2017 → Dec 2018 | renal cell carcinoma | Heidelberg Pharma AG | Withdrawn | No outcome recorded |
| Phase 3 | NCT00606632 | Mar 2008 → Nov 2009 | renal cell carcinoma | Heidelberg Pharma AG | Completed | No outcome recorded |
| Phase 3 | NCT00087022 | Jul 2004 → Oct 2012 | kidney cancer | Heidelberg Pharma AG | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00602862 | Jul 2007 → Apr 2012 | clear cell renal carcinoma | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Girentuximab | “The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT radiopharmaceutical for the...” NCT04897763 ↗6“Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.” PMID 22980441 ↗ Aug 2012 “PET/CT and contrast-enhanced CT (CECT) of the abdomen were performed 2 to 6 days after intravenous (124)I-girentuximab administration” PMID 23213092 ↗ Dec 2012 |
| Known as | 131I-cG250 | “Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)” NCT00003102 ↗ |
| Known as | 89Zr-Girentuximab | “89Zr-TLX250 (89Zr-girentuximab) PET/CT performed for all aptients” NCT04897763 ↗ |
| Known as | 89Zr-TLX250 | “The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT radiopharmaceutical for the...” NCT04897763 ↗ |
| Known as | cG250 | “OBJECTIVE: We determined the maximum tolerated dose (MTD) and potential therapeutic efficacy of multiple infusions of lutetium 177 ((177)Lu)-girentuximab (cG250) on various...” PMID 22980441 ↗ Aug 2012 |
| Known as | chimeric G250 | “The antibody we will use in this study is called chimeric G250 (cG250).” NCT00199888 ↗ |
| Known as | G250 | “Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)” NCT00003102 ↗ |
| Known as | GmAb | “Girentuximab (GmAb), a monoclonal antibody, is tagged with zirconium-89, a radioactive atom (which is also known as an isotope).” NCT06447103 ↗ |
| Action | Inhibit | “One possible method of interfering with the function of G250 is to target G250 with an antibody known as cG250.” NCT00520533 ↗ |
| Modality | Monoclonal antibody | “cG250 is an IgG1 chimeric monoclonal antibody.” NCT00003102 ↗ |
| Route | Intravenous | “administered intravenously (IV) over 10 minutes.” NCT00003102 ↗ |
| Target | CA9 | “anti-carbonic anhydrase IX monoclonal antibody” PMID 22980441 ↗ Aug 2012 |